Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Lancet
Jessica L MegaMarc S Sabatine

Abstract

Warfarin is the most widely used oral anticoagulant worldwide, but serious bleeding complications are common. We tested whether genetic variants can identify patients who are at increased risk of bleeding with warfarin and, consequently, those who would derive a greater safety benefit with a direct oral anticoagulant rather than warfarin. ENGAGE AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrillation were assigned to warfarin to achieve a target international normalised ratio of 2·0-3·0, or to higher-dose (60 mg) or lower-dose (30 mg) edoxaban once daily. A subgroup of patients was included in a prespecified genetic analysis and genotyped for variants in CYP2C9 and VKORC1. The results were used to create three genotype functional bins (normal, sensitive, and highly sensitive responders to warfarin). This trial is registered with ClinicalTrials.gov, number NCT00781391. 14,348 patients were included in the genetic analysis. Of 4833 taking warfarin, 2982 (61·7%) were classified as normal responders, 1711 (35·4%) as sensitive responders, and 140 (2·9%) as highly sensitive responders. Compared with normal responders, sensitive and highly sensitive responders spent greater proportions of time over-a...Continue Reading

References

Jun 13, 2001·JAMA : the Journal of the American Medical Association·B F GageM J Radford
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mitchell K HigashiAllan E Rettie
Jun 3, 2005·The New England Journal of Medicine·Mark J RiederAllan E Rettie
Oct 19, 2006·JAMA : the Journal of the American Medical Association·Daniel S BudnitzJoseph L Annest
Jan 31, 2009·Journal of Clinical Pharmacology·Myong-Jin KimLawrence J Lesko
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Mar 8, 2013·Circulation·Guillaume ParéLars Wallentin
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Nov 21, 2013·The New England Journal of Medicine·Talitha I VerhoefUNKNOWN EU-PACT Group
Nov 21, 2013·The New England Journal of Medicine·Stephen E KimmelUNKNOWN COAG Investigators
Nov 21, 2013·The New England Journal of Medicine·Munir PirmohamedUNKNOWN EU-PACT Group
Dec 18, 2013·The New England Journal of Medicine·Issam ZinehJanet Woodcock
Feb 8, 2014·Clinical Pharmacology and Therapeutics·J A RothD L Veenstra

❮ Previous
Next ❯

Citations

Feb 16, 2016·Current Opinion in Pharmacology·William L Baker, Samuel G Johnson
Dec 15, 2015·Expert Review of Cardiovascular Therapy·Gualtiero Palareti, Daniela Poli
Nov 13, 2015·Expert Opinion on Pharmacotherapy·Mikhail S Dzeshka, Gregory Y H Lip
Oct 16, 2015·Thrombosis and Haemostasis·J I Weitz, J Eikelboom
Dec 10, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Susannah L CollinsMunir Pirmohamed
Mar 24, 2016·Journal of Internal Medicine·G Y H LipC Blomström-Lundqvist
Sep 16, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Paul L McCormack
May 8, 2015·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Richard M TurnerMunir Pirmohamed
Jun 3, 2015·Journal of Clinical Pharmacy and Therapeutics·A StewartM Pirmohamed
Apr 29, 2016·Thrombosis and Haemostasis·Payman ShahabiNeda Gharani
Apr 30, 2016·The American Journal of Medicine·Christian T RuffJeffrey I Weitz
Jun 15, 2016·American Heart Journal·James A ReiffelUNKNOWN Cardiac Safety Research Consortium presenters and participants
Feb 6, 2016·Blood·Srikanth Nagalla, Paul F Bray
Jun 9, 2016·The Pharmacogenomics Journal·T I VerhoefM Pirmohamed
Aug 16, 2016·Clinics in Laboratory Medicine·Cheryl L MaierCharles E Hill
Sep 11, 2016·Trends in Cardiovascular Medicine·Faisal F Syed, Hakan Oral
Jul 8, 2016·Pharmacogenetics and Genomics·Benjamin FrenchStephen E Kimmel
Sep 18, 2016·Hematology/oncology Clinics of North America·Anna PlittRobert P Giugliano
Oct 18, 2016·Pharmacogenetics and Genomics·Otito F IwuchukwuC Michael Stein
Nov 5, 2016·Pharmacogenomics·Fannie MottetSimon de Denus
Dec 15, 2016·Pharmacogenomics·Georgia RagiaVangelis G Manolopoulos
Dec 19, 2015·Therapeutic Advances in Cardiovascular Disease·Alon Eisen, Christian T Ruff
Apr 8, 2017·Mayo Clinic Proceedings·John R GiudicessiMichael J Ackerman
Dec 14, 2017·Journal of Personalized Medicine·Theodore J WigleRichard B Kim
Dec 29, 2017·Journal of Personalized Medicine·Ann K DalyJohn O Miners
Sep 18, 2015·Therapeutic Advances in Cardiovascular Disease·Delilah McCarty, April Robinson
Jun 4, 2016·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Gary E MarchantDoug Campos-Outcalt
Sep 19, 2017·International Dental Journal·Sharonit Sahar-HelftMordechai Findler
May 2, 2018·Personalized Medicine·Alan Hb Wu
Feb 20, 2016·Circulation Research·Nina P PaynterDaniel I Chasman
Dec 15, 2017·Circulation. Cardiovascular Genetics·Kourosh RavvazPeter J Tonellato
Jan 20, 2019·Journal of Personalized Medicine·Sri H Kanuri, Rolf P Kreutz
Nov 20, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Larisa H CavallariJulie A Johnson
Mar 1, 2019·Clinical Pharmacokinetics·Minami OharaHarumi Takahashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.